Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial

Rizvi, NA; Cho, BC; Reinmuth, N; Lee, KH; Luft, A; Ahn, MJ; van den Heuvel, MM; Cobo, M; Vicente, D; Smolin, A; Moiseyenko, V; Antonia, SJ; Le Moulec, S; Robinet, G; Natale, R; Schneider, J; Shepherd, FA; Geater, SL; Garon, EB; Kim, ES; Goldberg, SB; Nakagawa, K; Raja, R; Higgs, BW; Boothman, AM; Zhao, L; Scheuring, U; Stockman, PK; Chand, VK; Peters, S – 2020 – 10.1001/jamaoncol.2020.0237